Amneal makes and sells generic, specialty and injectable medicines and distributes pharmaceuticals to government and retail buyers. AMRX reports earnings on Tue, Nov 3, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print.
Prices, price targets and earnings estimates for AMRX are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AMRX is in one of them and how their past AMRX trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Amneal Pharmaceuticals
Amneal develops, makes, markets and distributes medicines through three business areas. Its Affordable Medicines segment offers retail generic drugs, injectable products and biosimilars, while its Specialty segment sells branded drugs mainly for central nervous system and endocrine disorders. Its AvKARE unit distributes pharmaceuticals and other products to the U.S. federal government, retail customers and institutional buyers. The company operates mainly in the United States, India and Ireland.
